TAC-D Tablet is a combination antimicrobial formulation developed to combat a wide range of mixed infections caused by bacteria and protozoa. It is typically composed of Tinidazole, a synthetic antiprotozoal and antibacterial agent, and Ofloxacin, a fluoroquinolone antibiotic. This dual-action composition allows for comprehensive treatment of gastrointestinal, urinary, and gynecological infections caused by multiple pathogens.

Tinidazole in the TAC-D Tablet is effective against anaerobic bacteria and protozoal parasites such as Giardia lamblia, Entamoeba histolytica, and Trichomonas vaginalis. It works by damaging the DNA structure of the pathogens, thereby inhibiting their ability to multiply and survive. Ofloxacin, on the other hand, works by interfering with bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial replication and repair. Together, they deliver a synergistic action that rapidly alleviates infection symptoms while preventing recurrence.

TAC-D Tablet is commonly indicated in cases of amoebiasis, giardiasis, trichomoniasis, pelvic inflammatory disease, bacterial vaginosis, urinary tract infections, traveler’s diarrhea, and post-surgical infectious complications. The medication is well tolerated and is known for its quick onset of action and sustained therapeutic effects. It is particularly beneficial in settings where infections are suspected to be polymicrobial, making empirical therapy more effective.

This product is manufactured by Bluepill Express under internationally recognized standards including WHO-GMP, ISO, and other certifications required for export-quality pharmaceutical production. Every batch of TAC-D Tablet undergoes rigorous quality checks for purity, potency, and stability. The tablet is processed using advanced equipment and is packaged in secure blister or strip formats that ensure protection from moisture and contamination.

As a third-party manufacturer, Bluepill Express offers customizable options for TAC-D Tablet, including private labeling, regional language printing, and tailored packaging formats suited to the client’s market. Complete technical documentation such as COA, MOA, batch manufacturing records, and stability data are provided to meet regulatory requirements in various countries. The company supports clients from formulation development to market launch, providing turnkey solutions for domestic and international pharmaceutical markets.

TAC-D Tablet offers significant value for both prescribers and patients. It simplifies treatment by combining two potent agents into a single tablet, reducing pill burden and improving compliance. It is particularly useful in outpatient departments, general practice, and hospitals, where rapid, reliable treatment of suspected mixed infections is essential.